PCM
KNSA icon

Peregrine Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Peregrine Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
161,464
-19,896
-11% -$1.03M 0.34% 86
2026
Q1 		$8.73M Sell
181,360
-29,550
-14% -$1.31M 0.32% 85
2025
Q4 		$8.7M Sell
210,910
-3,454
-2% -$139K 0.27% 105
2025
Q3 		$8.32M Sell
214,364
-74,272
-26% -$2.41M 0.25% 109
2025
Q2 		$7.99M Sell
288,636
-20,554
-7% -$523K 0.24% 115
2025
Q1 		$6.87M Buy
309,190
+65,147
+27% +$1.34M 0.23% 125
2024
Q4 		$4.83M Buy
244,043
+4,361
+2% +$99.5K 0.14% 227
2024
Q3 		$5.99M Buy
239,682
+526
+0.2% +$12.8K 0.18% 179
2024
Q2 		$4.47M Buy
239,156
+3,111
+1% +$58.3K 0.13% 237
2024
Q1 		$4.66M Buy
+236,045
New +$4.61M 0.13% 238

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Peregrine Capital Management's KNSA Position: Q2 2026 in Review

Peregrine Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 11% in Q2 2026, selling an estimated $1.03M and leaving 161,464 shares worth $10.3M. The position accounts for 0.34% of the portfolio, ranked #86.

Peregrine Capital Management first reported a position in KNSA in Q1 2024 and has held it in 10 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Peregrine Capital Management held 161,464 shares of Kiniksa Pharmaceuticals worth $10.3M as of Q2 2026.
  • Peregrine Capital Management sold 19,896 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.03M.
  • Kiniksa Pharmaceuticals made up 0.34% of Peregrine Capital Management's portfolio in Q2 2026, its #86 holding.
  • Peregrine Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.